Paper26918878
Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.
Quaglia A and 17 others. Histopathology, 2016. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Papers, record 26918878. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26918878
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liver Diseases | Major topic |
| Acute Disease | |
| Biopsy | |
| Carcinoma, Hepatocellular | |
| Chronic Disease | |
| Disease Progression | |
| Humans | |
| Liver | |
| Liver Cirrhosis | |
| Liver Neoplasms | |
| Liver Regeneration | |
| Male | |
| Middle Aged | |
| Parenchymal Tissue |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41594255 | Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/41594255 | PubMed |
| 40875093 | Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/40875093 | PubMed |
| 38482630 | Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B. | Saudi J Gastroenterol | 2024 | https://conductscience.org/library/papers/38482630 | PubMed |
| 37511628 | Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511628 | PubMed |
| 36195966 | ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/36195966 | PubMed |
| 35043290 | Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis. | Eur Radiol | 2022 | https://conductscience.org/library/papers/35043290 | PubMed |
| 34909303 | A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India. | Cureus | 2021 | https://conductscience.org/library/papers/34909303 | PubMed |
| 31391527 | Utility of glutamine synthetase immunohistochemistry in identifying features of regressed cirrhosis. | Mod Pathol | 2020 | https://conductscience.org/library/papers/31391527 | PubMed |
| 29700417 | Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. | Mod Pathol | 2018 | https://conductscience.org/library/papers/29700417 | PubMed |
| 29589101 | Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. | Virchows Arch | 2018 | https://conductscience.org/library/papers/29589101 | PubMed |
| 28834875 | Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28834875 | PubMed |
| 28725770 | Strategies for a Successful Anatomic Pathology Subspecialty Workgroup: The 26-Year Collaboration of "The Elves". | Acad Pathol | 2016 | https://conductscience.org/library/papers/28725770 | PubMed |
| 28710435 | Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection. | Sci Rep | 2017 | https://conductscience.org/library/papers/28710435 | PubMed |
| 28415736 | The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. | Oncotarget | 2017 | https://conductscience.org/library/papers/28415736 | PubMed |
| 28328813 | Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28328813 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26918878
GET https://conductscience.org/api/papers/v1/26918878/authors